Zymeworks (NYSE:ZYME) had its price target upped to $18.00 by Canaccord Genuity in an issued report announced 5/24/2017. The latest target price indicates a possible upside of 0.37% from the company's most recent stock price close.
Previously on Tuesday May 23, 2017, Barclays Capital released a statement about Zymeworks (NYSE:ZYME) upped the target price from $0.00 to $20.00. At the time, this indicated a possible upside of 0.52%.
With a total market value of $0, Zymeworks has 52 week low of $6.25 and a 52 week high of $14.25 .
Brief Synopsis On Zymeworks (NYSE:ZYME)
Zymeworks Inc is a Canada-based clinical-stage biopharmaceutical company. The Company focuses on the discovery, development and commercialization of multifunctional biotherapeutics. The Company's ZymeCAD platform is for protein modeling and structure-guided protein engineering. The Company's platforms include Azymetric Platform, AlbuCORE Platform, EFECT Platform and Zymelink Conjugation Platform + Cytotoxins. The Company's lead product candidate, ZW25, is a bispecific antibody, which is being evaluated in an adaptive Phase I clinical trial. Its ZW33 is a bi-specific antibody that delivers a cytotoxic payload to cancers cells by binding to different epitopes (bi-paratopic targeting) of the overexpressed HER2 protein. It focuses on developing a pipeline of preclinical product candidates and discovery-stage programs in immuno-oncology and other therapeutic areas. It analyzes protein characteristics to develop the scope of protein engineering to tackle biological systems.
The post Zymeworks (NYSE:ZYME) target price raised to $18.00, reported today by Canaccord Genuity appeared first on Octafinance.